Latest News for PHCUF
Photocure ASA (PHCUF) M&A Call Transcript
OSLO, Norway, June 4, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO), a leader in bladder cancer diagnostics, today announced the signing and successful completion of its acquisition of Vesica Health, a U.S. established precision diagnostics company advancing AssureMDx, a urine-based molecular test for the early detection of bladder cancer, in a transaction designed to expand Photocure's position across the bladder…
Photocure ASA (PHCUF) Q1 2026 Earnings Call Transcript
OSLO, Norway, May 7, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO) today reported Hexvix ® /Cysview ® revenues of NOK 139.0 million in the first quarter of 2026 (Q1 2025: NOK 125.3 million), and an adjusted EBITDA of NOK 15.3 million (Q1 2025: NOK 9.7 million) for the company. In 2026, Photocure expects product revenue growth in the range of 7% to 11% on a constant currency basis and adjusted EBITDA margin expansion.
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for PHCUF.
Senate Trading
No Senate trades found for PHCUF.
U.S. House Trading
No House trades found for PHCUF.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.